⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVB News
Nuvation Bio Inc.
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
prnewswire.com
NUVB
Nuvation Bio to Participate in Upcoming Investor Conferences
prnewswire.com
NUVB
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
prnewswire.com
IBRX
NVCR
ONCY
NUVB
CATX
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
prnewswire.com
NVCR
IBRX
ONCY
CATX
NUVB
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
businesswire.com
NUVB
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
businesswire.com
NUVB
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
businesswire.com
NUVB
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
prnewswire.com
NUVB
Nuvation Bio to Participate in Upcoming Investor Conferences
businesswire.com
NUVB
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
businesswire.com
NUVB